Tag Archives: NASDAQ:BMRN

Cantor Fitzgerald Reiterates a Buy Rating on BioMarin (BMRN)

Cantor Fitzgerald analyst Eliana Merle reiterated a Buy rating on BioMarin (NASDAQ: BMRN) yesterday and set a price target of $126. The company’s shares closed yesterday at $99.45. Merle observed: “. We reiterate our Overweight rating and $126 12-month PT.

BioMarin (BMRN) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Eliana Merle initiated coverage with a Buy rating on BioMarin (NASDAQ: BMRN) today and set a price target of $126. The company’s shares opened today at $97.97. Merle wrote: “. We are initiating coverage of Overweight rating

The EVP & GC of BioMarin (NASDAQ: BMRN) is Selling Shares

Today, the EVP & GC of BioMarin (NASDAQ: BMRN), George Eric Davis, sold shares of BMRN for $220.4K. In addition to George Eric Davis, 4 other BMRN executives reported Sell trades in the last month. See today’s analyst top recommended

Analysts Are Bullish on These Healthcare Stocks: BioMarin (BMRN), Editas Medicine Inc (EDIT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (NASDAQ:BMRN) and Editas Medicine Inc (NASDAQ:EDIT) with bullish sentiments. BioMarin (BMRN) In a report released yesterday, Liana Moussatos from Wedbush reiterated

The President of BioMarin (NASDAQ: BMRN) is Selling Shares

Today, the President of BioMarin (NASDAQ: BMRN), Henry Fuchs, sold shares of BMRN for $2.49M. Following Henry Fuchs’ last BMRN Sell transaction on May 31, 2016, the stock climbed by 10.4%. In addition to Henry Fuchs, one other BMRN executive

A Director at BioMarin (NASDAQ: BMRN) is Selling Shares

Today, a Director at BioMarin (NASDAQ: BMRN), Alan Lewis, sold shares of BMRN for $420.3K. Following Alan Lewis’ last BMRN Sell transaction on December 08, 2014, the stock climbed by 8.8%. See today’s analyst top recommended stocks >> Based on